Integra LifeSciences (NASDAQ:IART) Upgraded at Truist Financial

Integra LifeSciences (NASDAQ:IART) was upgraded by analysts at Truist Financial to a “hold” rating in a research note issued on Thursday, Zacks reports.

A number of other brokerages have also weighed in on IART. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday, June 18th. Wells Fargo & Company boosted their target price on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Citigroup restated a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Finally, UBS Group began coverage on Integra LifeSciences in a report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $18.86.

Integra LifeSciences Trading Down 1.2%

Shares of IART stock opened at $16.09 on Thursday. The stock has a market capitalization of $1.25 billion, a PE ratio of -178.76, a P/E/G ratio of 0.84 and a beta of 1.21. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The business has a 50-day moving average of $16.83 and a 200 day moving average of $15.17.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences will post 2.46 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently modified their holdings of the business. Sequoia Financial Advisors LLC lifted its stake in shares of Integra LifeSciences by 221.7% during the second quarter. Sequoia Financial Advisors LLC now owns 45,785 shares of the life sciences company’s stock worth $822,000 after buying an additional 31,552 shares during the period. WINTON GROUP Ltd acquired a new position in Integra LifeSciences in the second quarter valued at approximately $1,843,000. Integrated Wealth Concepts LLC purchased a new stake in Integra LifeSciences during the second quarter worth $84,000. Corient Private Wealth LP boosted its stake in shares of Integra LifeSciences by 66.9% during the 2nd quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock worth $409,000 after acquiring an additional 9,120 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock worth $26,241,000 after purchasing an additional 160,814 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.